These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38686195)

  • 1. Unveiling the potential of SLURP1 protein as a biomarker for prostate cancer screening.
    Yang T; Liu T; Lei T; Li T; Liu N; Zhang M
    Front Oncol; 2024; 14():1365615. PubMed ID: 38686195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables.
    Gabriele C; Aracri F; Prestagiacomo LE; Rota MA; Alba S; Tradigo G; Guzzi PH; Cuda G; Damiano R; Veltri P; Gaspari M
    Clin Proteomics; 2023 Nov; 20(1):52. PubMed ID: 37990292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.
    Haj-Ahmad TA; Abdalla MA; Haj-Ahmad Y
    J Cancer; 2014; 5(2):103-14. PubMed ID: 24494028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
    Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
    Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
    Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
    Front Oncol; 2021; 11():730638. PubMed ID: 34722271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.
    Wang CB; Chen SH; Zhao L; Jin X; Chen X; Ji J; Mo ZN; Wang FB
    Clin Transl Oncol; 2023 Mar; 25(3):758-767. PubMed ID: 36266386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer.
    Shen H; Zhang L; Zhou J; Chen Z; Yang G; Liao Y; Zhu M
    Med Sci Monit; 2017 Jan; 23():216-222. PubMed ID: 28085790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation.
    Bellei E; Caramaschi S; Giannico GA; Monari E; Martorana E; Reggiani Bonetti L; Bergamini S
    Diagnostics (Basel); 2023 Apr; 13(7):. PubMed ID: 37046536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
    Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
    BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy.
    Jin X; Ji J; Niu D; Yang Y; Tao S; Wan L; Xu B; Chen S; Wang F; Chen M
    Front Oncol; 2022; 12():904315. PubMed ID: 35795046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer.
    Wang C; Liu G; Liu Y; Yang Z; Xin W; Wang M; Li Y; Yang L; Mu H; Zhou C
    Front Oncol; 2022; 12():1004015. PubMed ID: 36276156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection.
    Zemskova MY; Marinets MV; Sivkov AV; Pavlova JV; Shibaev AN; Sorokin KS
    Front Oncol; 2020; 10():610647. PubMed ID: 33791193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
    Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.